By Thomas M. Burton and Betsy McKay
U.S. health authorities came close to simply warning about a
blood-clotting risk from Johnson & Johnson's Covid-19 vaccine,
but decided to recommend pausing use out of concern doctors would
improperly treat the condition, people familiar with the matter
Over the previous four weeks, American health officials had
become alarmed about similar blood-clotting conditions in Europe
involving a Covid-19 vaccine from AstraZeneca PLC, the people said.
The officials dug into a U.S. vaccine safety database and
identified the cases of great concern, but debated what action to
By last Monday night, the officials resolved that urgent action
was needed, the people said. Four of six women in the U.S. who
developed the blood clots days after vaccination had initially been
given heparin, according to the U.S. Centers for Disease Control
and Prevention. Its use could have worsened the patients'
condition, the people said.
That night, the country's top health officials agreed during a
one-hour Zoom meeting to take the strongest step: publicly
recommend pausing the vaccine's use while probing the adverse-event
cases, the people said.
Since the announcement, the Food and Drug Administration has
been studying other reports of additional blood-clotting cases
among people who received J&J's vaccine, but hasn't confirmed
whether any reflect the same phenomenon, the people said. Yet
officials are growing more persuaded, the people added, that the
six total cases reported so far are related to the shot.
Health officials are now looking at limiting the J&J vaccine
to older people, among options, and could make public a decision as
early as this week.
FDA officials are waiting to see what a vaccine advisory panel
to the CDC recommends, the people said. The two most likely options
are restricting the shot to an age group such as men and women over
50 years, or allowing a return to widespread use but with added a
warning about the benefits and risks of the shot.
The CDC panel, called the Advisory Committee on Immunization
Practices, is scheduled to meet Friday to review the pause, after
putting off a vote on how to proceed during an emergency meeting
Anthony Fauci, President Biden's chief medical adviser, said he
expects J&J's vaccine to return to use in the U.S. by Friday.
"I believe we'll be back with some sort of indication a little bit
different from before the pause," Dr. Fauci said on ABC.
Among the more than seven million people in the U.S. given
J&J's Covid-19 vaccine before the pause, the total of six were
reported to have developed cerebral-vein blood clots and also
registered low counts of the colorless cells in the blood known as
platelets that help the blood to clot.
J&J has said it is aware of the blood-clot cases and working
with health authorities. Company researchers recently sent a letter
to a medical journal saying there wasn't evidence to establish a
connection between the vaccine and the adverse events so far.
The recommended pause disrupted a mass vaccination campaign that
is racing to inoculate as many people as possible before
coronavirus variants emerge that could render vaccines less
effective. The campaign had been picking up steam partly due to the
launch of J&J's vaccine, which is easier to store and requires
only one dose.
After the announcement last Tuesday morning, states, cities and
communities were forced either to cancel appointments for
vaccinations with J&J's shot or to find doses of the
alternatives to give.
The FDA and CDC drew criticism from some health experts afraid
the agencies' joint recommendation would exacerbate fears among
those already hesitant to get vaccinated and set back a push to
develop the communitywide immunity needed to stop the virus from
Health and Human Services Secretary Xavier Becerra, CDC Director
Rochelle Walensky, FDA Acting Commissioner Janet Woodcock and
National Institute of Allergy and Infectious Diseases Director Dr.
Fauci weighed the implications of a public announcement, the people
The officials, along with Peter Marks, the FDA's vaccines chief,
decided that caution and safety should take precedence, the people
"It is imperative for healthcare workers to know that the
treatment of these clots is different than our current standard of
care," Dr. Walensky said during a White House briefing last
The private deliberations among top federal health officials
resulting in the recommendation to pause use of J&J's vaccine
haven't been reported before. The following account of the rapid
turn of events culminating in the recommendation is based on
interviews with people familiar with the discussions.
Helping the decision making, the people said, were two sources
for reports about the rare adverse events.
One source, the people said, was health regulators in Europe.
They had been looking into reports of unusual clotting cases
involving another vaccine, from AstraZeneca and the University of
The AstraZeneca-Oxford vaccine is based on a similar technology
as J&J's. Both viral-vector vaccines use a modified common-cold
virus to carry genetic instructions that teach a human cell to make
a version of the spike protein found on the surface of the Covid-19
virus. A vaccine recipient's body then reacts to the spikes and
forms immunity to Covid-19 infection.
In March, health authorities in several countries on the
continent restricted use of the AstraZeneca-Oxford shot to
investigate clotting cases. This month, European medicine
regulators extended their probe to J&J's Covid-19 vaccine.
Dr. Marks, director of the FDA center that regulates vaccines,
and colleagues grew intrigued about the risk of blood clots over
the past month. Cases in Europe related to the vaccine developed by
AstraZeneca and the University of Oxford were accumulating, the
FDA staffers became concerned the phenomenon also might be
related to J&J's vaccine already in use in the U.S., the people
The J&J reports came from the other source of blood-clot
cases: the Vaccine Adverse Event Reporting System. Doctors and the
public report safety issues to the three-decade-old database. The
people filing reports don't know whether the events are truly
vaccine-related, but the FDA and CDC investigate these.
The first report of a blood-clot case in a person who got the
J&J vaccine was filed March 19, the people said. By April 9,
the two agencies had pulled from the VAERS database several other
similar cases. FDA and CDC officials began suspecting J&J's
shot played a role, the people said.
Over the weekend of April 10 and 11, Dr. Marks and CDC's Dr.
Walensky sifted through the reports case by case.
By last Monday, VAERS had six reports, all involving women. One
had died, while others were or had been in intensive care.
The federal health officials worried the risk of clots might be
significantly greater than initially suspected, if the problem was
really focused just on younger women, one person said. About 1.5
million women between the ages of 18 and 50 years had gotten
J&J's vaccine by that time, according to the CDC.
Given the blood-clot cases involving people who got the
AstraZeneca-Oxford vaccine, the U.S. health officials also worried
about a "class effect" involving viral-vector vaccines, the people
At 8 p.m. last Monday, Health Secretary Becerra joined other
senior health officials in a Zoom meeting to discuss what to do,
the people said.
After a clinical review of the cases, participants in the
meeting discussed potential responses. One option was to warn
doctors against using heparin, one of the people said, since
heparin was often given to clotting patients.
Four of the six women were initially treated with heparin,
according to data the CDC and J&J later presented to the ACIP,
the agency's vaccine advisory panel.
In one case, doctors administered the medication to a
48-year-old woman after finding extensive blood clots in veins in
her brain and abdominal cavity, along with an alarmingly low count
of platelets in her blood.
Despite the heparin, blood clots continued to form, according to
an account J&J presented to the ACIP and a description of the
case in the New England Journal of Medicine.
The woman was switched to another blood thinner called
argatroban, along with intravenous immune globulin, according to
the J&J and NEJM accounts. Her platelet count improved
substantially over the next five days, but she remained critically
ill early last week. She had been vaccinated two weeks before
Discussion shifted to recommending a pause in use, one of the
people said, after participants discussed whether simply adding a
warning might trigger calls for stronger action. One concern: the
ACIP might convene and counsel such action while the cases were
The group quickly agreed that if there was going to be a push
for a pause in a few days, it would be safer to do so immediately
to avoid possible new clotting cases, one of the people said. Such
drastic action would also attract the kind of public attention that
could prompt reporting of any other blood-clot cases.
Participants regretted the announcement, to be made at 7 a.m.
the next morning, wouldn't leave time for fully notifying state
health authorities, the people said.
Yet it would mean people scheduled to get vaccinated that day,
especially those in the Eastern time zone, would know beforehand,
rather than learning the news while waiting in line for a shot.
Write to Thomas M. Burton at firstname.lastname@example.org and Betsy McKay
(END) Dow Jones Newswires
April 18, 2021 17:35 ET (21:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.